Matt O'Brien
Stock Analyst at Piper Sandler
(2.24)
# 2,654
Out of 4,876 analysts
179
Total ratings
43.62%
Success rate
-5.41%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Reiterates: Overweight | $125 → $145 | $130.06 | +11.49% | 12 | Jun 4, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $58.82 | +36.01% | 12 | May 9, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $20 → $12 | $5.87 | +104.43% | 9 | May 9, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $40 → $30 | $21.77 | +37.80% | 2 | May 8, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $90 | $85.04 | +5.83% | 11 | May 2, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $13 → $15 | $10.90 | +37.61% | 3 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $36 → $30 | $19.11 | +56.99% | 8 | May 1, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $180 → $165 | $101.06 | +63.27% | 10 | Apr 15, 2025 | |
| KMTS Kestra Medical Technologies | Initiates: Overweight | $27 | $17.90 | +50.84% | 1 | Mar 31, 2025 | |
| TELA TELA Bio | Downgrades: Neutral | $5 → $2 | $1.85 | +8.11% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $4.25 | -17.65% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $119.58 | +17.08% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $14.99 | +73.45% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $309.83 | +0.05% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $253.58 | +30.14% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $32.88 | +52.07% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $16.81 | -4.82% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $104.58 | +9.96% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $5.12 | +134.38% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $390.40 | +7.58% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $121.87 | +14.88% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $58.63 | +27.92% | 3 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $86.18 | +4.43% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $52.34 | +52.85% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $18.09 | +38.20% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.22 | +35.14% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $2.18 | +106.42% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $91.74 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.98 | +403.36% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $69.69 | +56.05% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $2.61 | +596.55% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $30.50 | +162.30% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $3.58 | +235.20% | 1 | Jun 24, 2020 |
TransMedics Group
Jun 4, 2025
Reiterates: Overweight
Price Target: $125 → $145
Current: $130.06
Upside: +11.49%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $58.82
Upside: +36.01%
CVRx, Inc.
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $5.87
Upside: +104.43%
OrthoPediatrics
May 8, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $21.77
Upside: +37.80%
DexCom
May 2, 2025
Maintains: Overweight
Price Target: $100 → $90
Current: $85.04
Upside: +5.83%
Alphatec Holdings
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $10.90
Upside: +37.61%
Tandem Diabetes Care
May 1, 2025
Maintains: Overweight
Price Target: $36 → $30
Current: $19.11
Upside: +56.99%
Glaukos
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $101.06
Upside: +63.27%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $17.90
Upside: +50.84%
TELA Bio
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.85
Upside: +8.11%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $4.25
Upside: -17.65%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $119.58
Upside: +17.08%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $14.99
Upside: +73.45%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $309.83
Upside: +0.05%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $253.58
Upside: +30.14%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $32.88
Upside: +52.07%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $16.81
Upside: -4.82%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $104.58
Upside: +9.96%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $5.12
Upside: +134.38%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $390.40
Upside: +7.58%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $121.87
Upside: +14.88%
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $58.63
Upside: +27.92%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $86.18
Upside: +4.43%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $52.34
Upside: +52.85%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $18.09
Upside: +38.20%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.22
Upside: +35.14%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $2.18
Upside: +106.42%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $91.74
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.98
Upside: +403.36%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $69.69
Upside: +56.05%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $2.61
Upside: +596.55%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $30.50
Upside: +162.30%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $3.58
Upside: +235.20%